Evidence map›Paper›PMID 40745291›Full record

ArticleBMC cancer2025

30-hydroxygambogic acid increases the efficacy of cisplatin in an HPV

Sonia N Whang, Valeria Rodarte, Trevor Lohman, Josh Barforough, Lennox Chitsike, Gina N Lucas, David Lee, Caleb Ruiz-Jimenez, Yan Chen Wongworawat, Rouba Ali-Fehmi and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sonia N WhangDepartment of Basic Science, School of Medicine, Loma Linda University, 11021 Campus Street, Alumni Hall 101, Loma Linda, CA, 92350, USA.
Valeria RodarteDepartment of Basic Science, School of Medicine, Loma Linda University, 11021 Campus Street, Alumni Hall 101, Loma Linda, CA, 92350, USA.
Trevor LohmanSchool of Allied Health Professions, Loma Linda University, Loma Linda, CA, 92350, USA.
Josh BarforoughDepartment of Basic Science, School of Medicine, Loma Linda University, 11021 Campus Street, Alumni Hall 101, Loma Linda, CA, 92350, USA.
Lennox ChitsikeDepartment of Basic Science, School of Medicine, Loma Linda University, 11021 Campus Street, Alumni Hall 101, Loma Linda, CA, 92350, USA.
Gina N LucasDepartment of Basic Science, School of Medicine, Loma Linda University, 11021 Campus Street, Alumni Hall 101, Loma Linda, CA, 92350, USA.
David LeeDepartment of Basic Science, School of Medicine, Loma Linda University, 11021 Campus Street, Alumni Hall 101, Loma Linda, CA, 92350, USA.
Caleb Ruiz-JimenezDepartment of Basic Science, School of Medicine, Loma Linda University, 11021 Campus Street, Alumni Hall 101, Loma Linda, CA, 92350, USA.
Yan Chen WongworawatDepartment of Pathology and Human Anatomy, Loma Linda University Medical Center, Loma Linda, CA, 92350, USA.
Rouba Ali-FehmiDepartment of Pathology, Michigan Medicine, University of Michigan, Ann Arbor, MI, 48109, USA.
Marya WahidiDepartment of Pathology, Michigan Medicine, University of Michigan, Ann Arbor, MI, 48109, USA.
Juli UnternaehrerDepartment of Basic Science, School of Medicine, Loma Linda University, 11021 Campus Street, Alumni Hall 101, Loma Linda, CA, 92350, USA.
Valery FilippovDepartment of Basic Science, School of Medicine, Loma Linda University, 11021 Campus Street, Alumni Hall 101, Loma Linda, CA, 92350, USA.
Penelope J Duerksen-HughesDepartment of Basic Science, School of Medicine, Loma Linda University, 11021 Campus Street, Alumni Hall 101, Loma Linda, CA, 92350, USA. pdhughes@llu.edu.

Funding

HTS Screening for Inhibitors of HPV 16 E6/Caspase 8 BindingR21NS073059 · NINDS · LOMA LINDA UNIVERSITY · PI DUERKSEN-HUGHES, PENELOPE J · 2010 to 2013
$200k
NIH HHS R21 NS073059NINDS NIH HHS R21 NS073059
6 · The paper itself

Abstract

backgroundHead and neck squamous cell carcinoma (HNSCC) affects more than half a million people annually, and nearly 80% of oropharyngeal cancer cases are caused by human papillomavirus (HPV). Current treatments include chemo- and radiotherapy, though the effectiveness of these therapies is limited by the viral oncoprotein E6, which disrupts apoptotic pathways by binding and accelerating the degradation of molecules such as E6AP and caspase-8. Our lab has identified an E6 inhibitor, 30-hydroxygambogic acid (GA-OH), that is able to maintain these apoptotic signaling molecules.

methodTo further explore the therapeutic potential of this small molecule, we determined its antitumor efficacy in vivo. We developed an optimized xenograft model for HPV+ HNSCC, assessed GA-OH’s toxicity, and evaluated the effectiveness of GA-OH in combination with chemotherapy utilizing the optimized concentration of 0.6 mg/kg.

resultsGA-OH significantly increases (* p = 0.0105) cisplatin’s efficacy in HPV+ HNSCC in vivo without overt clinical manifestations. The only toxicities noted were a 4-fold increase in creatine kinase (**** p < 0.0001) and a 2.4-fold increase in aspartate aminotransferase (** p = 0.0057) in the cisplatin and GA-OH combination group compared to the vehicle group.

conclusionThe small molecule GA-OH was tolerable in our murine model, significantly amplifying the efficacy of cisplatin treatment.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCisplatinHead and Neck NeoplasmsPapillomavirus InfectionsSquamous Cell Carcinoma of Head and NeckAnimalsApoptosisCell Line, TumorDisease Models, AnimalDrug SynergismFemaleHuman Papillomavirus VirusesHumansMiceXenograft Model Antitumor AssaysCisplatin30-hydroxygambogic acid (GA-OH)Combination therapyHead and neck cancerHead and neck squamous cell carcinoma (HNSCC)HPV+ mouse xenograftHuman papillomavirus (HPV)Small molecule

Identifiers

PMID40745291
PMCPMC12315334

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.